The pharmacokinetics of cytarabine administered subcutaneously, combined with prednisone, in dogs with meningoencephalomyelitis of unknown etiology.
Autor: | Pastina B; College of Veterinary Medicine, North Carolina State University, Raleigh, North Carolina., Early PJ; College of Veterinary Medicine, North Carolina State University, Raleigh, North Carolina., Bergman RL; Carolina Veterinary Specialists, Matthews, North Carolina., Nettifee J; College of Veterinary Medicine, North Carolina State University, Raleigh, North Carolina., Maller A; Madison Veterinary Specialists, Madison, Wisconsin., Bray KY; Carolina Veterinary Specialists, Winston Salem, North Carolina., Waldron RJ; Upstate Veterinary Specialist, Greenville, South Carolina., Castel AM; College of Veterinary Medicine, University of Tennessee, C247 Veterinary Teaching Hospital, Knoxville, Tennessee., Munana KR; College of Veterinary Medicine, North Carolina State University, Raleigh, North Carolina., Papich MG; College of Veterinary Medicine, North Carolina State University, Raleigh, North Carolina., Messenger KM; College of Veterinary Medicine, North Carolina State University, Raleigh, North Carolina. |
---|---|
Jazyk: | angličtina |
Zdroj: | Journal of veterinary pharmacology and therapeutics [J Vet Pharmacol Ther] 2018 Oct; Vol. 41 (5), pp. 638-643. Date of Electronic Publication: 2018 May 15. |
DOI: | 10.1111/jvp.12667 |
Abstrakt: | The objective of this study was to describe the pharmacokinetics (PK) of cytarabine (CA) after subcutaneous (SC) administration to dogs with meningoencephalomyelitis of unknown etiology (MUE). Twelve dogs received a single SC dose of CA at 50 mg/m 2 as part of treatment of MUE. A sparse sampling technique was used to collect four blood samples from each dog from 0 to 360 min after administration. All dogs were concurrently receiving prednisone (0.5-2 mg kg -1 day -1 ). Plasma CA concentrations were measured by HPLC, and pharmacokinetic parameters were estimated using nonlinear mixed-effects modeling (NLME). Plasma drug concentrations ranged from 0.05 to 2.8 μg/ml. The population estimate (CV%) for elimination half-life and Tmax of cytarabine in dogs was 1.09 (21.93) hr and 0.55 (51.03) hr, respectively. The volume of distribution per fraction absorbed was 976.31 (10.85%) ml/kg. Mean plasma concentration of CA for all dogs was above 1.0 μg/ml at the 30-, 60-, 90-, and 120-min time points. In this study, the pharmacokinetics of CA in dogs with MUE after a single 50 mg/m 2 SC injection in dogs was similar to what has been previously reported in healthy beagles; there was moderate variability in the population estimates in this clinical population of dogs. (© 2018 John Wiley & Sons Ltd.) |
Databáze: | MEDLINE |
Externí odkaz: |